Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $60.62, moving -2.38% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.55% for ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

What you need to know about Ark Invest, an active ETF firm led by Cathie Wood that invests in disruptive, high-growth tech ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day.

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

ARK Invest isn’t letting go of its crypto conviction. Fresh filings reveal that the fund scooped another $8.2M worth of ...

CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.